SUMMARY
Research in the Kwon Lab focuses on methods to evoke a potent immune response to treat relatively advanced forms of malignancy. Specific areas of research pertain to the preclinical and clinical use of novel vaccines and antibodies to activate antitumoral T cells; the use of hormone manipulations to boost or rebuild host immunity; the treatment of patients with immunotherapy in order to induce clinical tumor regression. A special emphasis is placed on developing highly state-of-the-art immunotherapies to be tested in clinical phase I or II trials to treat patients with prostate, kidney or bladder cancer.
Research in the Kwon Lab is supported by a DOD NI Award (PC 991568), DOD IDEA Award (PC020574), NCI/NIH R01 (CA82185), a CaPCure Award and a new DOD-sponsored multi-center Phase II Trial Award (DAMD 17-02-1-0245 & DAMD 17-02-1-0245S1) entitled "A phase II immunotherapeutic trial; combined androgen ablative therapy and CTLA-4 blockade as a treatment for advanced prostate cancer".